Loading market dashboard

Estimates, scoring, valuation assumptions, and peer comparison in one research surface.
United Therapeutics Corporation · Forecast overview
Bars show expected revenue while the line tracks expected EPS.
| Period | Revenue avg | Revenue range | EBITDA | EPS avg | Analysts |
|---|---|---|---|---|---|
| Dec 2030 | $6.19B | $5.65B - $6.89B | $4.25B | $56.844 | 5 |
| Dec 2029 | $5.13B | $4.69B - $5.72B | $3.53B | $47.297 | 5 |
| Dec 2028 | $4.27B | $4.27B - $4.27B | $2.94B | $39.164 | 10 |
| Dec 2027 | $3.70B | $3.30B - $4.38B | $2.54B | $33.033 | 11 |
| Dec 2026 | $3.25B | $3.20B - $3.39B | $2.24B | $28.425 | 11 |
| Dec 2025 | $3.20B | $3.16B - $3.25B | $2.20B | $27.479 | 9 |
| Dec 2024 | $2.87B | $2.83B - $2.94B | $1.98B | $24.407 | 10 |
| Dec 2023 | $2.62B | $2.39B - $2.92B | $1.80B | $23.072 | 5 |
| Dec 2022 | $1.96B | $1.84B - $2.04B | $751.43M | $17.516 | 4 |
| Dec 2021 | $1.70B | $1.60B - $1.77B | $683.12M | $11.381 | 5 |
| Dec 2020 | $1.46B | $1.37B - $1.52B | $341.35M | $12.768 | 5 |
| Dec 2019 | $1.50B | $1.41B - $1.56B | -$3.00B | -$0.82 | 4 |